Jiangsu Kanion Pharmaceutical Gets NMPA Go-Ahead for Psoriasis Drug Clinical Trial
Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a prominent pharmaceutical company based in China, has...
Genesis MedTech Secures NMPA Approval for Innovative Surgical Energy Products
Genesis MedTech, a leading medical device company headquartered in Singapore, has secured marketing approvals from...
True Health’s Advanced Microwave Ablation System Gains NMPA Nod for Liver Tumor Treatment
True Health (Guangdong Hengqin) Medical Technology Co., Ltd has received marketing approval from China’s National...
Venus Medtech Initiates Global Study with Venus Vitae TAVR System Implantations
Venus Medtech (Hangzhou) Inc., listed on the Hong Kong Stock Exchange as HKG: 2500, has...
China’s Hainan Free Trade Port Implements ‘Zero Tax’ on Medical Imports for Designated Entities
In a joint effort to bolster healthcare services, China’s Ministry of Finance, National Health Commission...
Viatris Launches First-of-Its-Kind Nasal Spray Dymista in China for Allergic Rhinitis
Viatris Inc. (NASDAQ: VTRS), a leading global pharmaceutical company based in the U.S., has announced...
Sansure Biotech Wins NMPA Nod for ALDH2 Gene Polymorphism Detection Kit
Sansure Biotech Inc., (SHA: 688289), a leading molecular diagnostics company based in China, has announced...
Novo Nordisk Advances in China with Submission of Sogroya for Adult Growth Hormone Deficiency
Denmark’s pharmaceutical heavyweight, Novo Nordisk (NYSE: NVO), has reached a significant milestone with the National...
AstraZeneca China Restructures Biopharma Unit to Boost Chronic Disease Management
AstraZeneca (NASDAQ: AZN)’s Chinese subsidiary has announced a strategic restructuring of its China biopharmaceutical business...
Kelun-Biotech’s ADC for Cancer Gets NMPA Review, Expands MSD Collaboration
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has achieved a regulatory milestone with its clinical...
Eli Lilly Partners with Haya Therapeutics to Tap the Dark Genome for Obesity Treatments
Eli Lilly & Co. (NYSE: LLY), a leading figure in the pharmaceutical industry, has embarked...
Roche’s Columvi for Relapsed DLBCL Gets Review Nod from China’s CDE for New Indication
The Center for Drug Evaluation (CDE) in China has accepted for review an additional indication...
Jiangsu Hengrui’s Ivarmacitinib for Adult Alopecia Areata Accepted for Review by China’s CDE
The Center for Drug Evaluation (CDE) has given the green light for the review of...
US Allows Science and Technology Agreement with China to Expire, Pointing to Deepening R&D Competition
The US-China Science and Technology Agreement (STA), a pivotal accord initially inked in 1979 by...
Novartis Builds Two Radioligand Therapy Facilities in U.S. to Expand Cancer Treatment Capabilities
Novartis AG (NYSE: NVS), a Swiss pharmaceutical giant listed on the NYSE under the ticker...
Jiangsu Suzhou Launches $843 Million Biomedicine Fund to Boost Pharma and Medical Device Innovation
The Jiangsu Suzhou Biomedicine Industry Special Fund of Fund (FoF), a colossal pharmaceutical investment vehicle...
Sage Group Expands into China’s Healthcare Market with Cenponts Healthcare Partnership
Sage Group, a UK-based financial advisory powerhouse, has announced a strategic foray into China’s burgeoning...
Hanx Biopharmaceuticals Receives NMPA Approval for HX009 Combination Therapy Phase II Trial
On September 5, 2024, China-based Hanx Biopharmaceuticals Co., Ltd announced that it has received approval...
E-commerce and Physical Stores to Stock Hanmi’s OTC Drugs Following Shanghai Pharma Deal
Hanmi Pharmaceutical, a leading South Korean pharmaceutical company, has reportedly entered into a supply agreement...
Aspen Pharmacare’s 2024 Fiscal Report Shows Mixed Results Amid China’s VBP Impact
Aspen Pharmacare Holdings Ltd (JSE: APN), a leading South African pharmaceutical company, has reported its...